marijuana stocks news

Will GW Pharmaceuticals (GWPH) Miss this Earnings Season? – Analyst Blog

GW Pharmaceuticals plc (GWPH) is set to report first-quarter fiscal 2015 results on Feb 4, before the market opens. Last quarter, the company posted a positive earnings surprise of 104.35%. Let’s see how things are shaping up for this announcement.

Factors at Play This Quarter

The company’s key growth driver, Sativex, approved outside the U.S. for the treatment of spasticity associated with multiple sclerosis, should continue to perform well in the first quarter of 2015. GW Pharma expects strong Sativex revenues driven by higher in-market sales.

The company expects a significant increase in cash burn in anticipation of the potential launch of Sativex in the U.S. and continued investments in the pipeline, particularly on Epidiolex.

Investor focus should remain on pipeline updates since a number of pipeline related activities are lined up for the rest of 2015.

Last month, the company reported top-line data from the first of three phase III studies on Sativex for the treatment of pain in patients suffering from advanced cancer who have experienced inadequate analgesia during optimized chronic opioid therapy. The drug failed to meet the primary endpoint in the study. However, the company plans to file a new drug application with the FDA provided results from two ongoing additional pivotal phase III studies on Sativex, are positive. Data from the studies are expected later in the year.

While GW Pharma has completed enrolling patients in part A of a phase II/III study on Epidiolex for the treatment of Dravet syndrome, enrollment into part B is expected to commence shortly. Data from phase III studies on Epidiolex is expected by the end of 2015. In addition to this, the company intends to initiate two pivotal phase III studies on Epidiolex for the treatment of Lennox-Gastaut syndrome shortly.

Earnings Whispers?

Our proven model does not conclusively show that GW Pharma is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 for this to happen. This is not the case here, as you will see below.

Zacks ESP: The Earnings ESP for GW Pharma is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate are at a loss of 91 cents per share.

Zacks Rank: GW Pharma carries a Zacks Rank #3 (Hold). GW Pharma’s Zacks Rank #3 when combined with an ESP of 0.00% makes surprise prediction difficult.

We caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.

Stocks That Warrant a Look

Regeneron Pharmaceuticals, Inc. (REGN) has an Earnings ESP of +8.65% and a Zacks Rank #3. The company is scheduled to release results on Feb 10.

Actavis (ACT) has an Earnings ESP of +4.7% and it carries a Zacks Rank #3. The company is scheduled to release results on Feb 18.

The earnings ESP for Ariad Pharmaceuticals Inc. (ARIA) is +50.00% and it carries a Zacks Rank #3. The company is scheduled to release results on Feb 19.

 


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

 4Front Ventures Corp. (FFNTF) Fiscal Second Quarter 2020 Earnings Date and Conference Call

4Front Announces Fiscal Second Quarter 2020 Earnings Date and Conference Call 4Front…

$GRNH Initiates the First Phase of Its Multi-Faceted Collaboration

Greengro Technologies Initiates the First Phase of Its Multi-Faceted Collaboration With Affiliate…

Verano Holdings Corp. (VRNOF) Announces 2021 Fourth Quarter and Full Year U.S. GAAP Financial Results

Verano Announces 2021 Fourth Quarter and Full Year U.S. GAAP Financial Results…

$CARA to Webcast Presentation at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference

Cara Therapeutics to Webcast Presentation at 22nd Annual BioCentury Future Leaders in…